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Abstract
With the aging of the population with colorectal cancer, there is a need for a more personalized approach of
these older patients. The present study demonstrates that the performance of a geriatric assessment identiﬁes
problems and predicts functional decline during treatment as well as chemotherapy-related toxicity. Geriatric
assessments should be integrated in the care of older patients with colorectal cancer.
Introduction: This study aims to evaluate the relevance of geriatric assessment (GA) in older patients with colorectal
cancer (CRC) and to study functional status (FS) and chemotherapy-related toxicity during treatment. Methods:
Patients with CRC aged  70 years were evaluated at baseline using a GA. Results were communicated to the treating
physician. At 2 to 3 months follow-up, FS was reassessed, and chemotherapy-related toxicity was recorded. Results:
A total of 193 patients, with a median age of 77 years, were included. GA was abnormal in 75% and revealed unknown
problems in 40%. Treatment was altered in 37% based on clinical assessment. GA led to geriatric interventions in 9
patients (5%) and additionally inﬂuenced treatment in 1 patient. At follow-up (n ¼ 164), functional decline was
observed in 29 patients (18%) for activities of daily living (ADL) and in 60 patients (37%) for instrumental activities of
daily living (IADL). Baseline IADL, depression, fatigue, and cognition were predictors for ADL decline, whereas no
predictors for IADL decline could be identiﬁed. In the 109 patients receiving chemotherapy, stage and baseline fatigue
were predictive for grade 3/4 hematologic toxicity, and baseline ADL, fatigue, and nutrition were predictive for grade 3/
4 nonhematologic toxicity. Conclusion: Although GA identiﬁed previously unknown problems in more than one-third
of older CRC patients, the impact on interventions or treatment decisions was limited. Baseline GA parameters may
predict functional decline and chemotherapy-related toxicity. Education of physicians treating older patients with CRC
is an essential step in the implementation of GA and subsequent interventions.
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The prevalence of colorectal cancer (CRC) increases with age.
Over 50% of patients with newly diagnosed CRC are older than 70
years of age.1 With the aging of the population, it is expected that
the incidence of CRC in this older population will rise further.L.D. and L.V. contributed equally to this work as ﬁrst authors.
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Geriatric Assessment in Colorectal Cancercomorbidities and polypharmacy. The Eastern Cooperative
Oncology Group (ECOG) performance status (PS) and standard
clinical approach fail to evaluate those aspects speciﬁcally for older
patients with cancer.5
Geriatric medicine has developed a multidimensional geriatric
assessment (GA)6 to identify deﬁcits missed by routine examination.
It includes social parameters, functional status (FS) and fall history,
cognitive and psychological status, nutritional status, comorbidities
and polypharmacy, and uses validated geriatric scales to identify frail
patients and subsequently set up an individualized geriatric inter-
vention plan.
In older patients with cancer, GA is feasible at large scale and
detects unknown geriatric problems.7,8 In addition, GA and sub-
sequent interventions can improve quality of life and seem to be
prognostic and predictive.8 In older patients with CRC, GA can
predict treatment-related toxicity and postoperative morbidity.9,10
The aim of the present study was to investigate the value of GA
in older patients with CRC as well as its inﬂuence on cancer
treatment decisions. Secondly, the study evaluated the evolution of
FS during treatment and the development of chemotherapy-related
severe toxicity.
Methods
Patient Population
We performed a prospective noninterventional cohort study on
GA in older patients with cancer in 6 tumor types (breast cancer,
CRC, lung cancer, ovarian cancer, prostate cancer, and hematologic
malignancies) in 2 Belgian academic hospitals.7 The ethical com-
mittees of both participating centers approved the study (protocol
number S51815).
Patients 70 years and older with newly diagnosed cancer or
cancer progression/relapse were included when a cancer treatment
decision had to be made. Disease progression/relapse was deﬁned as
progression during treatment or relapse after a treatment-free in-
terval. A written informed consent was obtained from all patients.
For the present study, we performed a subanalysis on the cohort
of patients with CRC.
Geriatric Screening and GA
At baseline, a trained health care worker performed a geriatric
screening and GA in all patients, as previously described.7 Geriatric
screening was performed with the Flemish version of the Triage
Risk Screening Tool (fTRST) and G8.11-13 The GA included: pain
assessment, social data, FS by the Katz Activities of Daily Living
(ADL) and by the Lawton Instrumental Activities of Daily Living
(IADL), fall history during the last year, fatigue assessed by the
Mobility Tiredness scale (MOB-T), mental status by the Mini
Mental State Examination (MMSE) and Geriatric Depression Scale
(GDS-15), nutritional status by the Mini Nutritional Assessment-
Short Form (MNA-SF), comorbidities by the Charlson Comor-
bidity Index (CCI), and a polypharmacy assessment.12
A geriatric risk proﬁle was deﬁned as having 2 or more of the
following criteria: living alone, ADL > 6, IADL < 8 for females
or < 5 for males, MMSE < 24/30, GDS > 5/15, MNA-SF < 24/
30, and CCI  1.
The GA results were communicated to the treating physician
electronically or on paper prior to the ﬁnal cancer treatmentnical Colorectal Cancer Month 2016decisions. It was at the physician’s discretion to consult this infor-
mation for the ﬁnal cancer treatment plan. If deemed necessary, the
initial treatment plan could be modiﬁed, and speciﬁc interventions
could be performed.
Geriatric interventions consisted of referrals to the geriatrician,
social worker, physiotherapist, psychologist, dietician, geriatric day
clinic, fall clinic, and other.
Questionnaires for the Treating Physician
After the ﬁnal treatment decision, the treating physician was
interviewed using a predeﬁned questionnaire. First, the ques-
tionnaire contained 3 questions on the GA: (1) Were you aware of
GA results at the time of treatment decision? (2) Did the GA
reveal any new information? and (3) Was any action undertaken
to deal with the problems detected by the GA? Second, the
questionnaire included 3 main questions on the impact of age and
GA on cancer treatment decisions: (1) What would be your
oncologic treatment proposal if the patient was 55 years old
without comorbidities? (2) Is this different from your treatment
proposal for this older patient according to age and standard
clinical assessment without information from the GA? If yes, what
was your treatment proposal for this patient and why? and (3) Is
this different from your current treatment proposal for this patient
according to age and standard clinical approach with the knowl-
edge of GA results? If yes, what is your current treatment proposal
for this patient and why?
The treatment proposed for a 55-year old patient without
comorbidities (answer to question 1) was considered as standard. If
the answer to the second question was afﬁrmative, treatment was
considered changed based on clinical assessment including age.
Only physicians who consulted the GA results before the ﬁnal
treatment decision could answer the third question on treatment
decisions. If the answer to this question was afﬁrmative, treatment
was considered modiﬁed based on GA results.
Functional Decline
The FS of patients was reassessed 2 to 3 months after the cancer
treatment decision by repeating the ADL and IADL. Functional
decline on the ADL was deﬁned as an increase of 2 or more points
on the total score, and on IADL as a decrease of 1 or more points on
the total score.12
Chemotherapy-Related Toxicity
For patients treated with chemotherapy, grade 3/4 toxicity, ac-
cording to the common terminology criteria for adverse events,
v4.0, was retrospectively recorded.14 Hematologic and non-
hematologic toxicity were analyzed separately.
Data Analysis
Data were analyzed using SAS v9.3. For continuous data, mean,
median, 95% conﬁdence intervals (CIs), and range were assessed.
For categorical data, frequency and 95% CI were assessed. Cate-
gorical data were compared using the c2 test.
Determination of predictors of functional decline on the ADL
and IADL and of grade 3/4 hematologic and nonhematologic
chemotherapy toxicity was performed separately using logistic
regression. Univariate logistic regressions were conducted on the
Table 1 Patients and Clinical Characteristics (n [ 193)
Characteristic N %
Age, years
Median (range) 77 (70-89)
Gender
Female 73 37.8
Male 120 62.2
Colorectal carcinoma stage
Stage I 13 6.7
Stage II 25 13
Stage III 25 13
Stage IV 130 67.3
ECOG PS
0 104 53.9
1 41 21.2
2 23 11.9
3 22 11.4
4 2 1
M 1 0.5
Treatment
Surgery 86 44.6
Radiotherapy 18 7
Chemotherapy 109 56.5
Adjuvant 18
Palliative 91
Abbreviation: ECOG PS ¼ Eastern Cooperative Oncology Group Performance Status.
Figure 1 Flow Chart of Patient Selection
Lore Decoster et alfunctional decline of the ADL and IADL in all patients and on
hematologic toxicity and nonhematologic toxicity in patients
receiving chemotherapy.
For functional decline, the following baseline categorical variables
were used: age (70-74/75-79/ 80 years), time point of assessment
(new diagnosis vs. disease progression/relapse), stage (I-III vs. IV),
ECOG PS (score 0-1 vs. score 2-4), fTRST ( 1), G8 ( 14),
baseline ADL (> 6), and IADL (< 5 [male]/8 [female]), living
situation (living alone), fall history in the past 12 months (reported
fall history), fatigue by MOB-T (presence of fatigue), cognition by
MMSE (< 24), depression by GDS-15 ( 5), nutrition by
MNA-SF ( 11), comorbidities by CCI ( 1), polypharmacy ( 5
different drugs), surgery, radiotherapy, and chemotherapy.
For chemotherapy-related toxicity, surgery, radiotherapy, and
chemotherapy were excluded from the analysis. In addition, for
nonhematologic toxicity, cognition by MMSE was excluded owing
to a complete separation of data points.
Multivariable logistic regressions were conducted on the func-
tional decline of the ADL and IADL and on grade 3/4 hemato-
logic and nonhematologic chemotherapy-related toxicity, using
stepwise variable selection and P-values to enter and to stay in the
model of, respectively, .20 and .15. Only variables signiﬁcant in
the univariate setting were considered for the multivariable
regressions.
Results
Patient Characteristics
From October 2009 till July 2011, 937 patients were included of
which 193 were patients with CRC (Table 1).
Median age in the CRC cohort was 77 years (range, 70-89 years).
The majority (67%) of patients had stage IV disease.
At follow up, 2 to 3 months after inclusion, the data of 164
patients (85%) were available (Figure 1).
Results of Baseline Geriatric Screening and Assessment
The screening tools fTRST and G8 were abnormal in 156 (81%)
and 145 (75%) patients, respectively (Table 2).
A geriatric risk proﬁle by GA was observed in 144 (75%) pa-
tients. Deﬁciencies were observed in all GA domains, with risk for
malnutrition being the most frequent in 130 (67%) patients. At
baseline, 93 patients (48%) showed dependency on ADL and 111
patients (58%) on IADL.
Ninety-six of 145 patients (66%) with ECOG PS < 2 and all 47
patients with ECOG PS  2 had a geriatric risk proﬁle, according to
the GA.
Inﬂuence of Clinical Assessment (Including Age) and GA
on Cancer Treatment Decisions
The questionnaire for the treating physician was completed in
183 of 193 patients (95%).
Treatment was adapted based on clinical assessment in 67 pa-
tients (37%; 95% CI, 30%-49%) (Table 3), mostly for systemic
therapy including chemotherapy and targeted therapy (60 patients):
6 patients received the standard regimen at reduced dose, 20 pa-
tients received a less toxic regimen at standard dose, 4 patients
received a less toxic regimen at reduced dose, and 30 patients did
not receive systemic therapy.Standard treatment was not given to 9 of 46 patients with a
normal GA (20%; 95% CI, 8.4%-31.6%) and to 58 of 137 pa-
tients with an abnormal GA (42%; 95% CI, 33.7%-50.3%)
(P ¼ .006).Clinical Colorectal Cancer Month 2016 - 3
Table 2 Results of the Baseline Geriatric Screening and Assessment
Item/Instrument Score N %
Screening fTRST (0-6) Absence of a geriatric risk proﬁle: score 0 37 19.2
Presence of a geriatric risk proﬁle: score 1 156 80.8
G8 (0-17) Absence of a geriatric risk proﬁle: score >14 48 24.9
Presence of a geriatric risk proﬁle: score 14 145 75.1
Geriatric assessment
Social data Living situation Alone 48 24.9
Not alone 145 75.1
Functional status ADL (6-24) Independent: score ¼ 6 100 51.8
Dependent: score 7 93 48.2
IADL (0-5/8) Independent: score ¼ 8 (female) or ¼ 5 (male) 82 42.5
Dependent: score <8 (female) or <5 (male) 111 57.5
Falls history in the past 12 months No falls 135 70
1 falls 58 30
Fatigue MOBT-T (0-6) No fatigue 62 32.1
Presence of fatigue 131 67.9
Cognition MMSE (0-30) Normal cognition: score 24 177 91.7
Mild/severe cognitive decline: score <24 16 8.3
Depression GDS (0-15) Not at risk for depression: score <5 155 80.3
At risk for depression: score 5 38 19.7
Nutrition MNA (0-30) Normal nutritional status score 24 85 44
At risk for malnutrition score <24 108 56
Co-morbidities CCI (0-37) No comorbidities: score ¼ 0 81 42
Co-morbidities: score 1 112 58
Polypharmacy Number of different drugs 0-4 106 55
5 82 42.4
M 5 2.6
Abbreviations: ADL ¼ activities of daily living; CCI ¼ Charlson Comorbidity Index; fTRST ¼ Flemish version of the Triage Risk Screening Tool; GA ¼ geriatric assessment; GDS ¼ Geriatric Depression
Scale; IADL ¼ instrumental activities of daily living; M ¼ missing data; MMSE ¼ Mini Mental State Examination; MNA ¼ Mini Nutritional Assessment; MOB-T ¼ Mobility e Tiredness Test.
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the GA results for 78 (43%) patients.
The GA revealed unknown geriatric problems in 40%, mainly
concerning fall history (15%), risk of depression (11%), and
functional dependency (11%). In 9 patients (5%), the identiﬁed
problems led to a directed intervention, including consultation of a
social worker (1%), a geriatrician (1.5%), a psychologist (0.5%),
and a dietician (2%).
The results of the GA led to an additional change of treatment in
1 patient: palliative care instead of chemotherapy in a patient with
stage IV CRC.
Functional Decline at Follow-Up
At 2 to 3 months follow-up (n ¼ 164), 73 (45%) patients were
dependent on ADL and 98 (60%) on IADL.
Functional decline for ADL and IADL was observed in 29 (18%)
and 60 patients (37%), respectively. There was no signiﬁcant dif-
ference in functional decline between the baseline independent and
dependent group for ADL (P ¼ .570) and IADL (P ¼ .763).
Table 4 describes univariate and multivariable analysis in all
patients for prediction of decline in ADL and IADL. In multivariate
analysis, a decline in ADL was predicted by baseline IADL (oddsnical Colorectal Cancer Month 2016ratio [OR], 0.42), fatigue (OR, 0.37); cognition (OR, 0.37), and
risk of depression (OR, 0.44). No predictors for IADL decline were
identiﬁed.
Chemotherapy-Related Toxicity at Follow-Up
A total of 109 patients were treated with systemic therapy, of
which 18 were adjuvant and 91 were for advanced disease, including
ﬂuorouracil or capecitabin in 20 patients (18%), combination
chemotherapy in 37 patients (34%), combination of chemotherapy
with bevacizumab in 20 patients (18%), combination of chemo-
therapy with anti-epidermal growth factor receptor antibody in 14
patients (13%), study protocol in 7 patients (6%), and other
options in 11 patients (10%). Patients with advanced stage disease
(stage III or IV) more frequently received systemic treatment than
patients with early stage disease (stage I or II) (103 of 155 [66.5%]
vs. 6 of 38 [15.8%], respectively [P < .001]).
Twenty-seven of 109 (25%) patients treated with systemic
therapy experienced grade 3/4 toxicity. Twenty-one patients
demonstrated nonhematologic grade 3/4 toxicity, including
gastrointestinal toxicity (n ¼ 10), cardiovascular adverse events
(n ¼ 4), stomatitis (n ¼ 2), hand-foot syndrome (n ¼ 2), peripheral
neuropathy (n ¼ 1), and dyspnea (n ¼ 2). Hematologic toxicity
Table 3 Inﬂuence of Clinical Assessment (Including Age) on
Cancer Treatment Decision in Older Patients With
Colorectal Cancer, Based on Answers to the Second
Question on the Questionnaire for the Treating Phy-
sicians (N [ 183)
Differences in Cancer Treatment Decision
in Older Versus Younger/Fit Patients N %
Chemotherapy 60 32.8
Standard schedule at reduced dose 6 3.3
Less toxic schedule at standard dose 20 10.9
Less toxic schedule at reduced dose 4 2.2
No chemotherapy 30 16.4
Surgery 22 12.6
Less extensive surgery 1 0.5
No surgery 4 2.2
Radiotherapy 8 4.5
Less extensive radiotherapy 4 2.2
Radiotherapy instead of surgery/chemotherapy 1 0.5
No radiotherapy 3 1.6
Lore Decoster et aloccurred in 6 patients, of which 3 were grade 3 anemia, 2 were
febrile neutropenia, and 1 was grade 3 neutropenia.
Table 5 describes univariate and multivariable analysis in patients
receiving chemotherapy for prediction of hematologic and non-
hematologic grade 3/4 toxicity. For hematologic toxicity, multi-
variate analysis identiﬁed stage of disease (OR, 6.60) and baseline
fatigue (OR, 8.15) as predictive factors. For nonhematologic
toxicity, baseline nutrition (OR, 0.33), fatigue (OR, 0.30), and
ADL (OR, 2.62) were predictive factors.
Discussion
Physicians treating CRC are confronted with a growing number
of older patients, a group underrepresented in clinical trials.2 It is
unclear whether treatment regimens that are beneﬁcial for younger
patients are also the best choice for the older population, given their
heterogeneity in physiologic reserves, comorbidities, FS, and
cognition. This heterogeneity provides a major challenge, requiring
an individualized and multidisciplinary approach.
For the present study, we performed a subanalysis of older pa-
tients with CRC included in a large prospective study evaluating the
performance of GA in older patients with cancer.7,12,15 In 193
patients with CRC aged  70 years, a GA was performed before the
ﬁnal cancer treatment decision.
The current analysis suggests that, in more than one-third (37%)
of older patients with CRC, treatment decisions are inﬂuenced by
clinical assessment (including age), mainly regarding systemic
treatment. This supports previous data that older patients with
CRC are less likely to undergo surgery3 or to receive systemic
treatment both in the adjuvant and palliative settings.4 In addition,
it seems that the multidisciplinary decision-making regarding
chemotherapy for CRC is often made without face-to-face contact
between the patient and the discussants, and that chronologic age is
a frequent motivation for omission of chemotherapy.4 Other patient
characteristics such as comorbidity were considered less impor-
tant.16 In the current study, 20% of patients considered ﬁt by GAdid not receive standard treatment. Although different reasons may
be responsible, including patient choice, a proportion of our older
patients with CRC were probably undertreated. This is in contrast
to data demonstrating a similar beneﬁt for ﬁt older and younger
patients with CRC for surgery and chemotherapy17 and a similar
tolerance to commonly used chemotherapy regimens, provided
there is adequate supportive care.1 On the other hand, 58% of
patients considered at risk by GA did receive standard treatment,
which may sometimes be appropriate, providing supportive in-
terventions, but a proportion of patients may also be overtreated
because oncologists often overestimate the ﬁtness of older patients
with cancer for chemotherapy.5 For this reason, the performance of
a GA may enhance personalized treatment for older patients with
CRC and subsequently prevent under- and overtreatment.
In the current study, 66% of patients with an ECOG PS < 2
demonstrated a geriatric risk proﬁle according to the GA. This was
conﬁrmed by Jolly et al: of 796 older patients with cancer with a
good professional and self-rated Karnofsky PS ( 80), 69% had at
least 1 GA-identiﬁed deﬁcit.18 In this heterogeneous population,
commonly used PS scales seem inferior to GA for selection of ﬁt
from unﬁt patients, mainly because PS scales are normally assigned
using cancer-related FS and not to comorbidities. In addition, GA
may predict surgical morbidity19 and chemotherapy-related
toxicity.20,21
In the present study, 75% of patients demonstrated an abnormal
GA, with deﬁciencies observed in all domains, mostly for nutrition
and FS. These deﬁciencies were unknown in 40% of patients,
mainly concerning falls, risk of depression, and FS, but only
sporadically led to subsequent geriatric interventions. The reasons
for this may be multiple, including the patient’s wish and irrele-
vance owing to advanced stage of cancer, but in older patients
without cancer, geriatric interventions have shown to improve the
FS and survival.22 In the present study, the number of patients
receiving geriatric interventions or a GA-adapted treatment regimen
is too small to draw further conclusions on the impact of GA on
outcome measures such as toxicity and functional decline. For this
reason, intervention studies based on GA in older patients with
CRC are needed in order to evaluate the impact of such personal-
ized treatment on these different outcome measures.
Although the results of the GA were communicated to the
treating physician before the ﬁnal cancer treatment decision, we
observed that only a minority of the physicians actually consulted
them. This indicates that there is a need to educate physicians
treating CRC on the beneﬁts of GA. The International Society of
Geriatric Oncology organizes such educational programs in order to
train physicians (both cancer specialists and geriatricians) in the
personalized care of older patients with cancer and to enhance
cooperation with geriatric departments.
It is important for physicians to realize that FS is an important
factor for quality of life in older patients and that active life ex-
pectancy is more important than life expectancy as such.23 In the
present study, a decline in FS was observed in 18% for ADL and in
37% for IADL. A similar observation was made in surgically treated
older patients with CRC where an ADL and IADL decrease was
observed from the pre- to the postoperative condition.24 Similarly,
the IADL decrease was the most pronounced, illustrating that more
complex activities are affected to a higher degree than basic dailyClinical Colorectal Cancer Month 2016 - 5
Table 4 Univariate and Multivariable Predictors of Functional Decline on ADL/IADL
Variable Operationalization
ADL Decline IADL Decline
Univariate Multivariable Univariate Multivariable
P Value P Value OR 95%CI P Value P Value OR 95%CI
Age, years 70-74 vs. 75-79 vs. 80 .990 .832
Timepoint of assessment New diagnosis vs. progression/relapse .590 .722
Stage of disease I-III vs. IV .488 .771
ECOG PS Score 0-1 vs. 2-4 .008 e .735
fTRST No geriatric proﬁle vs. geriatric proﬁle .352 .376
G8 No geriatric proﬁle vs. geriatric proﬁle .081 e .305
Living situation Living alone vs. living with help .675 .706
ADL ADL independent vs. ADL dependent .455 .769
IADL IADL independent vs. IADL dependent .004 .016 0.42 0.15-1.18 .544
Falls history in the past 12 months No falls vs. falls .060 e .250
Fatigue by MOB-T No fatigue vs. fatigue .005 .066 0.37 0.13-1.04 .350
MMSE Normal cognition vs. mild/severe cognitive
decline
.023 .136 0.37 0.10-1.41 .415
GDS-15 Not at risk vs. at risk for depression .004 .004 0.44 0.16-1.20 .307
MNA-SF Normal nutritional status vs. at risk for
malnutrition/malnourished
.165 e .448
CCI No comorbidities vs. comorbidities .909 .985
Polypharmacy 0-4 different drugs vs. 5 different drugs .873 .262
Surgery No surgery vs. surgery .599 .500
Radiotherapy No radiotherapy vs. radiotherapy .208 .213
Chemotherapy No chemotherapy vs. chemotherapy .613 .182 e
P values in bold indicate those values signiﬁcant to enter the multivariable regression for the univariate analysis (P < .20) and to stay in the multivariable regression for the multivariable analysis (P ¼ .15).
Abbreviations: ADL ¼ activities of daily living; CCI ¼ Charlson Comorbidity Index; CI ¼ conﬁdence interval; ECOG-PS ¼ Eastern Cooperative Oncology Group Performance Status; fTRST ¼ Flemish version of the Triage Risk Screening Tool; GDS-15 ¼ 15 item Geriatric
Depression Scale; IADL ¼ instrumental activities of daily living; MMSE ¼ Mini Mental State Examination; MNA-SF ¼ Mini Nutritional Assessment e Short Form; MOB-T ¼ Mobility e Tiredness Test; OR ¼ odds ratio.
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Table 5 Univariate and Multivariable Predictors of Grade 3/4 Hematologic and Nonhematologic Chemotherapy-Related Toxicity
Variable Operationalization
Grade 3/4 Hematologic Toxicity Grade 3/4 Nonhematologic Toxicity
Univariate Multivariable Univariate Multivariable
P Value P Value OR 95%CI P Value P Value OR 95%CI
Age, years 70-74 vs. 75-79 vs. 80 .313 .187 e
Timepoint of assessment New diagnosis vs. progression/relapse .108 e .934
Stage of disease I-III vs. IV .025 .040 6.6 1.09-39.8 .310
ECOG-PS Score 0-1 vs. 2-4 .237 .148
fTRST No geriatric proﬁle vs. geriatric proﬁle .740 .831
G8 No geriatric proﬁle vs. geriatric proﬁle .102 e .084 e
Living situation Living alone vs. living with help .697 .505
ADL ADL independent vs. ADL dependent .810 .214 .087 2.62 0.86-7.97
IADL IADL independent vs. IADL dependent .936 .934
Falls history in the past 12 months No falls vs. falls .935 .625
Fatigue by MOB-T No fatigue vs. fatigue .040 .067 8.2 0.87-76.8 .043 .120 0.30 0.09-1.01
MMSE Normal cognition vs. mild/severe
cognitive decline
.794 e
GDS-15 Not at risk vs. at risk for depression .890 .528
MNA-SF Normal nutritional status vs. at risk for
malnutrition/malnourished
.065 e .026 .026 0.33 0.09-1.27
CCI No comorbidities vs. comorbidities .328 .335
Polypharmacy 0-4 different drugs vs. 5 different drugs .337 .376
P values in bold indicate those values signiﬁcant to enter the multivariable regression for the univariate analysis (P < .20) and to stay in the multivariable regression for the multivariable analysis (P ¼ .15).
Abbreviations: ADL ¼ activities of daily living; CCI ¼ Charlson Comorbidity Index; CI ¼ conﬁdence interval; ECOG-PS ¼ Eastern Cooperative Oncology Group Performance Status; fTRST ¼ Flemish version of the Triage Risk Screening Tool; GDS-15 ¼ 15 item Geriatric
Depression Scale; IADL ¼ instrumental activities of daily living; MMSE ¼ Mini Mental State Examination; MNA-SF ¼ Mini Nutritional Assessment e Short Form; MOB-T ¼ Mobility e Tiredness Test; OR ¼ odds ratio.
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8 - Clifunctions. In a systematic review in patients treated for CRC with
curative intent, FS declined at 3 months after treatment and
improved again over time, although it was not fully back to baseline
at 1 year.25 Interestingly, a signiﬁcant number of patients experi-
enced a permanent FS decrease (31% for ADL and 61% for IADL
at 22 months). The identiﬁcation of predictive factors for FS decline
could guide treatment and interventions in order to prevent such
functional decline and consequently preserve quality of life. In our
study, baseline IADL, fatigue, depression, and cognition were found
to be predictive for ADL decline at 2 to 3 months, whereas no
predictive factors were identiﬁed for IADL decline. Interestingly,
treatment with chemotherapy was not predictive for FS decline in
our population.
Grade 3/4 chemotherapy-related toxicity occurred in a quarter of
patients treated with chemotherapy, mostly nonhematologic.
Baseline malnutrition, fatigue, and ADL were predictive for grade
3/4 nonhematologic toxicity, whereas stage and baseline fatigue
were predictive for grade 3/4 hematologic toxicity. Because patients
with advanced stage (III and IV) signiﬁcantly received systemic
treatment more frequently, these patients were more likely to
develop hematologic toxicity. In other studies in older patients with
CRC, malnutrition, cognition, and IADL were mentioned as pre-
dictive factors for chemotherapy-related toxicity.10,26 In addition,
GA seems to be predictive for treatment-related toxicity,20,21,27
postoperative morbidity,9 and decrease in quality of life.8 This il-
lustrates the relevance of GA in the treatment decision-making
process.
One important limitation of this study is the heterogeneity of the
population with CRC regarding stage and treatment. In addition,
because the current study was performed at 2 Belgian academic
centers, a referral bias may be present. Therefore, it may be difﬁcult
to apply our exact results to the overall populations of older patients
with CRC. In order to investigate the full impact of GA and geri-
atric interventions, a randomized clinical trial in a larger more ho-
mogeneous population would be necessary.
Conclusion
In conclusion, the treatment of older patients with CRC requires
careful consideration of multiple factors by the treating physician.
An evaluation by a GA will help to identify patients at risk for
adverse outcome and will help to develop a treatment plan incor-
porating medical and physical considerations, cancer- and
comorbidity-related outcomes, and the patient’s health and treat-
ment goals. In the absence of risk factors, GA may also prevent
undertreatment in ﬁt patients. For this reason, integration of GA in
routine clinical practice is of the utmost importance. To obtain this
goal, the International Society of Geriatric Oncology organizes
educational programs for all caregivers involved in the treatment of
older patients with cancer as well as for geriatricians in an order to
provide these physicians with the necessary skills to treat older pa-
tients with cancer multidisciplinary and to facilitate reciprocal
cooperation.28
Clinical Practice Points
 Although ﬁt older patients with CRC may derive beneﬁt from
surgery and chemotherapy, chronologic age is a frequent moti-
vation for the omission of therapy. For this reason, it has beennical Colorectal Cancer Month 2016stated that biologic age as determined by GA should be used to
decide if a patient is ﬁt or not to undergo treatment.
 The current study demonstrates that a GA is abnormal in a
substantial amount of older patients with CRC, even in the
subgroup with good ECOG PS, and frequently detects previ-
ously unknown problems. However, only a small percentage of
treating physicians actively consulted the results, and the impact
on the performance of directed interventions and on treatment
decisions remained limited. The study also demonstrates that
functional decline occurs frequently in older patients with CRC
during treatment and that GA parameters may be predictive for
functional decline and chemotherapy-related toxicity.
 These results clearly indicate the need to educate treating phy-
sicians on the usefulness of GA. Increasing cooperation between
geriatricians and physicians treating CRC will lead to a more
personalized therapy and directed interventions for older patients
and subsequently should prevent functional decline and
chemotherapy-related toxicity.Acknowledgment
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